GLPwatch
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
NCT06808802 · Completed
Last updated 2026-05-28This clinical trial is testing how the drug retatrutide affects the levels of metoprolol in the bloodstream of healthy participants.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design open-label (no blinding) basic-science study
Participants 30 people
Who can join Ages 21–65 · all sexes Healthy volunteers accepted.
Timeline Started 2025-02 · est. completion 2025-04
Where 1 site · Singapore
What this study is testing ClinicalTrials.gov NCT06808802 ↗
Description as written by the study sponsor.
The purpose of this study J1I-MC-GZQE is to measure the effect of retatrutide on the pharmacokinetics (PK) of metoprolol in healthy participants.
Treatments tested
- Retatrutide also known as LY3437943 Drug
Administered subcutaneously (SC)
- Metoprolol Drug
Administered orally
| Main thing measured | Pharmacokinetics (PK): Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol |
|---|---|
| Sponsor | Eli Lilly and Company |
| Conditions studied | Healthy |
| GLP-1 drugs | retatrutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06808802 ↗